Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.51 |
| ▸ | RAB9A | P51151 | 13/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209135 | 0.83 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2GRM4MAPT | |
| SCHEMBL4862360 | 0.83 | KDR (0.56) | NPC1RAB9ASMN1; SMN2MAPTPKM | |
| SCHEMBL14223875 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2GRM4MAPT | |
| SCHEMBL25393684 | 0.80 | KDR (0.59) | NPC1RAB9ASMN1; SMN2GRM4MAPT | |
| SCHEMBL14223457 | 0.80 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2GRM4MAPT | |
| SCHEMBL4854729 | 0.80 | KMT2A (0.51) | NPC1RAB9ASMN1; SMN2GRM4MAPT | |
| SCHEMBL4860965 | 0.79 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2GRM4MAPT | |
| SCHEMBL4855888 | 0.79 | RAB9A (0.71) | NPC1RAB9ASMN1; SMN2GRM4MAPT | |
| SCHEMBL25394146 | 0.78 | RAB9A (0.46) | NPC1RAB9ASMN1; SMN2GRM4MAPT | |
| SCHEMBL5594529 | 0.78 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | NPC1 1563/4885RAB9A 2079/4885SMN1; SMN2 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.